Nurix advances bexobrutideg to Phase 2 trial, raises $250M, but quarterly loss widens 55%

Filed April 8, 2026 · Period ending February 28, 2026 · Compared to 10-Q Apr 8, 2025 · ~1 min read

Key Changes

• high

  Bexobrutideg Phase 2 potentially-pivotal trial commenced October 2025 in triple-refractory CLL using FDA-agreed 600mg dose, marking progression from dose-finding to registration-directed study.

  MD&A: Clinical Development verify on EDGAR →
• high

  Quarterly net loss jumped 55% to $87.2M from $56.4M year-over-year as R&D spending increased $14.5M to support accelerated Phase 2 enrollment and trial preparation.

  MD&A: Operating Results verify on EDGAR →
• high

  Sanofi exercised exclusive licenses on two development candidates (March and May 2025), triggering $30M in fees and validating DEL-AI platform productivity.

  MD&A: Collaboration Revenue verify on EDGAR →